NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) — Attorney Advertising – Bronstein, Gewirtz & Grossman, LLC is notifying investors that a class action lawsuit has been filed against Fate Therapeutics, Inc. (“Fate” or the “Company”) FATE and certain of its officers on behalf of all persons and entities that purchased or otherwise acquired securities of Fate between April 2, 2020 and January 5, 2023, both dates inclusive (the “Collection Period”). Such investors are encouraged to join this case by visiting the company’s website: www.bgandg.com/fate.

This class action seeks damages against the defendants for alleged violations of federal securities laws.

The lawsuit alleges that the defendants made materially false and misleading statements regarding the Company’s business, operations and compliance policies throughout the class period. In particular, the Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Janssen Cooperation Agreement was less sustainable than Fate had represented to the investors; (ii) accordingly, certain clinical programs, milestone payments and royalties payments related to the Janssen Collaboration Agreement may not qualify as future revenue streams; (iii) as a result, Fate had overstated the impact of the Janssen Collaboration Agreement on Fate’s long-term clinical and commercial viability; and (iv) as a result, the Company’s public statements were, at all relevant times, materially false and misleading.

A class action lawsuit has already been filed. If you would like to see a copy of the complaint, you can visit the firm’s website: www.bgandg.com/fate or you can contact Peretz Bronstein, Esq. or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Fate, you have until March 22, 2023 to request that the court appoint you lead plaintiff. Your ability to participate in a recovery doesn’t require you to serve as a lead…